Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar
Becetti et al.,
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases..,
Qatar Medical Journal, doi:10.5339/qmj.2022.37
Retrospective 700 patients with autoimmune rheumatic disease in Qatar, showing lower risk of COVID-19 with HCQ use, without statistical significance. For patients having close contact with COVID-19 cases, there was a statistically significant association with HCQ use and lower risk of COVID-19 in unadjusted results.
risk of case, 36.8% lower, RR 0.63, p = 0.17, treatment 26 of 314 (8.3%), control 49 of 386 (12.7%), NNT 23, adjusted per study, odds ratio converted to relative risk, multivariable.
|
risk of case, 52.0% lower, RR 0.48, p < 0.001, treatment 16 of 46 (34.8%), control 29 of 40 (72.5%), NNT 2.7, patients with close contact to cases, close contact.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Becetti et al., 5 Aug 2022, retrospective, Qatar, peer-reviewed, mean age 43.2, 12 authors, study period 1 April, 2020 - 31 July, 2020.
Contact:
becettikarima@gmail.com.
Abstract: RESEARCH PAPER
Prevalence of coronavirus disease 2019 in a
multiethnic cohort of patients with autoimmune
rheumatic diseases in Qatar
Karima Becetti1*, Eman Satti1*, Betsy Varughese2, Yousef Al Rimawi1, Rawan Sheikh Saleh1,
Nawal Hadwan1, Miral H Gharib1, Mohamed Awni Al Kahlout1, Essa Abuhelaiqa3, Hadil Afif
Ashour1, Rajvir Singh4, Samar Al Emadi1
Address for Correspondence:
Karima Becetti, Eman Satti1*
1
Division of Rheumatology, Department of Medicine,
Hamad Medical Corporation, Doha, Qatar
2
Gastroenterology & Hepatology, Medicine, Hamad
Medical Corporation, Doha, Qatar
3
Division of Nephrology, Department of Medicine,
Hamad Medical Corporation, Doha, Qatar
4
Cardiology Research Center, Heart Hospital, Hamad
Medical Corporation, Doha, Qatar
*These authors contributed equally to this work
Email: becettikarima@gmail.com
http://doi.org/10.5339/qmj.2022.37
Submitted: 13 January 2022
Accepted: 25 May 2022
© 2022 Becetti, Satti, Varughese, Al Rimawi, Saleh, Hadwan,
Gharib, Al Kahlout, Abuhelaiqa, Ashour, Singh, Al Emadi,
licensee HBKU Press. This is an open access article distributed
under the terms of the Creative Commons Attribution license
CC BY 4.0, which permits unrestricted use, distribution and
reproduction in any medium, provided the original work is
properly cited.
Cite this article as: Becetti K, Satti E,
Varughese B, Al Rimawi Y, Saleh RS, Hadwan N,
Gharib MH, Al Kahlout MA, Abuhelaiqa E, Ashour
HA, Singh R, Al Emadi S. Prevalence of
coronavirus disease 2019 in a multiethnic cohort
of patients with autoimmune rheumatic diseases
in Qatar, Qatar Medical Journal 2022(3):37
http://doi.org/10.5339/qmj.2022.37
ABSTRACT
Background: Autoimmune rheumatic diseases (ARDs)
are characterized by immune dysfunction and
associated with an increased risk of infections, which
were of significant concern during the coronavirus
disease 2019 (COVID-19) pandemic. Variable rates
of COVID-19 incidence have been reported in
patients with ARDs; however, the true effect of this
infection on this patient population is still unclear. We,
therefore, aimed to evaluate the COVID-19 prevalence among a multiethnic cohort of patients with
ARDs in Qatar.
Material and Methods: We used telephonic surveys to
collect demographic and clinical information of
patients with ARD in Qatar between April 1 and July
31, 2020, including any close contact with a COVID19 case at home or work and polymerase chain
reaction (PCR)-confirmed COVID-19 diagnosis.
An electronic medical records review was conducted
to verify pertinent data collected through the
surveys. Prevalence with 95% confidence interval
(CI), Student’s t-tests, and chi-square/Fisher’s exact
tests were used for univariate analyses, whereas
multivariate logistic regression was used to identify
factors associated with COVID-19.
Results: The study included 700 patients with ARD
(mean age, 43.2 ^ 12.3 years), and 73% were
female. Until July 2020, 75 (11%, 95% CI 9% –13%)
patients had COVID-19. Factors associated with
COVID-19 included being a man (adjusted odds ratio
[aOR] 2.56, 95% CI 1.35–4.88, p ¼ 0.01) and
having close contact with a COVID-19 case (aOR
27.89, 95% CI 14.85–52.38, p ¼ 0.01). Disease
severity and rheumatic medications had no significant
QATAR MEDICAL JOURNAL 1
VOL. 2022 / ART. 37
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases
association with the odds of contracting COVID-19.
In the 86 patients with ARD having close contact,..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit